The global anti-obesity drugs market is projected to grow from USD 45.1 billion in 2026 to USD 106.5 billion by 2035, representing an approximately 10.0% compound annual growth rate, according to a report added to ResearchAndMarkets.com's offering. Rising obesity prevalence, stronger clinical evidence, next-generation medicines and broader access to prescription weight-loss therapies are expected to support expansion. More than one billion people worldwide are living with obesity, including approximately 880 million adults and 159 million children and adolescents, data compiled by the NCD Risk Factor Collaboration indicates. GLP-1 receptor agonists (medicines that activate GLP-1 pathways) containing semaglutide and tirzepatide are central to the market, while the SELECT cardiovascular outcomes trial found semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease. Oral candidates such as OPK-88006, orforglipron and ECC5004 could improve convenience and access if approved. Eli Lilly and Novo Nordisk currently lead the market, while Roche, Teva, Voy and other companies are expanding manufacturing, generic, digital-health and geographic strategies. North America currently generates the largest revenue share, while Asia-Pacific is projected to grow fastest through 2035. High research and development costs, regulatory requirements, manufacturing constraints, adverse events and long-term safety considerations remain key challenges.